The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.Source: electronic medicines compendium (emc), DatapharmActive substance: calcium carbonate, colecalciferol; cholecalciferolOfficial document: view the original leaflet on emc →Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

← Back to all medicines

Adcal D3 chewable tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Calcium carbonate, Colecalciferol; cholecalciferol may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Calcium carbonate, Colecalciferol; cholecalciferol

Equivalent medicines (same active substance, strength and form)

→ Accrete D3 film-coated tablets brand

→ Adcal D3 Lemon Chewable Tablets brand

Source: electronic medicines compendium (emc)

Official leaflet: Read the PIL on emc

What it is and what it is used for

for

Adcal-D3 contains calcium and vitamin D3 which are both essential for healthy bones and teeth. Adcal-D3 provides extra calcium and vitamin D3 to your diet. It is therefore used in conditions where your body's calcium and vitamin D levels need to be increased. –

Adcal-D3 can be prescribed by doctors for certain bone conditions, for example, osteoporosis.

Studies show that taking calcium and vitamin D3 over a long time can prevent hip and other nonvertebral bone fractures in later life. 2.

What you need to know before you take it

e Adcal-D3

Do not take Adcal-D3: − −

if you are allergic to calcium carbonate, vitamin D3 or any of the other ingredients of this medicine (listed in section 6) if you are allergic to peanut or soya. Adcal-D3 contains soya oil.

Warnings and precautions: Talk to your doctor or pharmacist before taking Adcal-D3. Tell your doctor or pharmacist if you: − − −

Have high levels of calcium in your blood (hypercalcaemia) or high levels of calcium in your urine (hypercalciuria). If you are unsure your doctor will advise you. Have problems with your kidneys, for example kidney stones. Have sarcoidosis (inflammation that produces lumps of cells in various organs in the body), your doctor will be able to tell you if you do.

− −

Have previously been told by your doctor that you have an intolerance to some sugars. Are taking any other medication, even those you may have bought for yourself without prescription.

Other medicines and Adcal-D3 Tell your doctor if you are taking calcium supplements or antacids for indigestion, digitalis drugs (eg. Lanoxin), diuretics or corticosteroids. If you are taking thyroxine, bisphosphonates, zinc, strontium ranelate and iron or fluoride medicines, tetracycline or quinolone antibiotics make sure your doctor knows this. When taking these medicines leave a period of about 4 hours before taking your Adcal-D3 tablets. Do not take them at the same time. Tell your doctor if you are taking orlistat as this may reduce absorption of vitamin D. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pregnancy and breast-feeding In pregnancy or when breast feeding, Adcal-D3 should only be used under medical supervision. Ask your doctor or pharmacist for advice before taking any medicine. Adcal-D3 with food This medicine should not be taken within 2 hours of eating foods rich in oxalic acid (e.g. spinach and rhubarb), phosphate (e.g. bran), or phytic acid (e.g. whole cereals). Adcal-D3 contains sucrose and soya oil Adcal-D3 contains a small amount of sugar and may be harmful to the teeth if used for a prolonged period. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. Adcal-D3 contains soya oil. If you are allergic to peanut or soya, do not use this medicine. 3.

How to take it

Adcal-D3

Always take this medicine exactly as described in this leaflet or as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Adults, elderly and children over 12 years of age: 2 tablets daily, ideally one tablet taken in the morning and one in the evening. Adcal-D3 tablets should be chewed. Do not swallow whole. Children under 12: Adcal-D3 must not be given to children under 12 years old. If you take more Adcal-D3 than you should

You should only take what your doctor recommends. If you take too many Adcal-D3 tablets contact your doctor or pharmacist if you can do so. If not, go to the nearest hospital casualty department immediately, taking the Adcal-D3 pack and remaining tablets with you. Signs of overdose may include frequent urge to urinate, loss of appetite, nausea or vomiting, unusual tiredness or weakness, along with high levels of calcium in the blood and kidney impairment. If you forget to take Adcal-D3 If you forget to take your tablet, take it as soon as possible and continue to take the tablets as normal. Do not take a double dose to make up for a forgotten tablet. If you stop taking Adcal-D3 Always talk to your doctor or pharmacist before stopping using Adcal-D3. If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4.

Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them. Frequency not known (frequency cannot be estimated from the available data): • Allergic reactions – symptoms include itching, wheezing, rash, swelling of the face, tongue, lips or throat. If you have an allergic reaction stop taking the tablets and seek medical attention immediately. Rare side effects (may affect up to 1 in 1,000 people): − Constipation, wind, feeling sick, stomach ache, diarrhoea. − Skin rash. − Hypercalcaemia (too much calcium in your blood) or hypercalciuria (too much calcium in your urine). If you are on long term treatment your doctor may, from time to time wish to check the level of calcium in your blood and take urine samples to monitor kidney function. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme: Website: www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine. 5.

How to store it

Adcal-D3

−

Keep this medicine out of the sight and reach of children. Do not store above 25oC. Do not use this medicine after the expiry date which is stated on the carton and blister strip has passed. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.

− − −

Contents of the pack and other information

What Adcal-D3 contains − The active substances are calcium carbonate (1500mg, equivalent to 600mg calcium) and vitamin D3 (400iu, equivalent to 10μg colecalciferol). − The other ingredients are xylitol (E967), modified maize starch, sodium saccharin (E954), magnesium stearate and 'Tutti-Frutti' flavouring (contains propylene glycol (E1520)). − The vitamin D3 compound contains DL-tocopherol, edible fats (including soya oil), gelatin, sucrose and corn starch. What Adcal-D3 looks like and contents of the pack − The tablets are white, flat faced and circular in shape. − Adcal-D3 tablets are provided in packs of 56 or 112 tablets. Marketing Authorisation Holder: Grünenthal Ltd TOR Building Saint Cloud Way Maidenhead Berkshire SL6 8BN United Kingdom

Manufacturer: Sopharma AD 16 Iliensko Shosse Str Sofia 1220 Bulgaria

Other sources of information If you have been prescribed Adcal-D3 Chewable Tablets for the treatment or prevention of osteoporosis and would like further information you should speak to your doctor or pharmacist. This leaflet was last revised in 11/2025

Frequently asked questions about Adcal D3 chewable tablets

How do I take Adcal D3 chewable tablets?

Adcal D3 chewable tablets comes as tablet. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Adcal D3 chewable tablets?

The active substance in Adcal D3 chewable tablets is calcium carbonate, colecalciferol; cholecalciferol.

Are there equivalent medicines to Adcal D3 chewable tablets?

Medicines with the same active substance, strength and form include: Accrete D3 film-coated tablets, Adcal D3 Lemon Chewable Tablets. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Adcal D3 chewable tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Adcal D3 chewable tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Source: electronic medicines compendium (emc), Datapharm
Active substance: calcium carbonate, colecalciferol; cholecalciferol
Official document: view the original leaflet on emc →

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Calcium carbonate (45 medicines), Calcium carbonate, colecalciferol; cholecalciferol (12 medicines), Colecalciferol; cholecalciferol (34 medicines)

See every medicine containing this substance, or browse the full A–Z of active substances.

⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+

Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

As an adjunct to specific therapy for osteoporosis and in situations requiring therapeutic supplementation of malnutrition e.g. in pregnancy and established vitamin D dependent osteomalacia.

The prevention and treatment of calcium deficiency/vitamin D deficiency especially in the housebound and institutionalised elderly subjects. Deficiency of the active moieties is indicated by raised levels of PTH, lowered 25-hydroxy vitamin D and raised alkaline phosphatase levels which are associated with increased bone loss.

4.2. Posology and method of administration

Oral.

Adults and Elderly and children above 12 years of age:

2 chewable tablets per day, preferably one tablet each morning and evening.

Children:

Not recommended for children under 12 years.

4.3. Contraindications

Absolute contra-indications are hypercalcaemia resulting for example from myeloma, bone metastases or other malignant bone disease, sarcoidosis; primary hyperparathyroidism and vitamin D overdosage. Severe renal failure. Hypersensitivity to any of the tablet ingredients.

Relative contra-indications are osteoporosis due to prolonged immobilisation, renal stones, severe hypercalciuria.

Adcal-D3 contains a small quantity of soya oil and is therefore contraindicated in patients who are allergic to peanuts or soya.

4.4. Special warnings and precautions for use

Patients with mild to moderate renal failure or mild hypercalciuria should be supervised carefully including periodic checks of plasma calcium levels and urinary calcium excretion.

In patients with a history of renal stones urinary calcium excretion should be measured to exclude hypercalciuria.

With long-term treatment it is advisable to monitor serum and urinary calcium levels and kidney function, and reduce or stop treatment temporarily if urinary calcium exceeds 7.5mmol/24 hours (300mg/24 hours).

During concomitant treatment with other high-dose sources of vitamin D and/or medications affecting serum calcium levels or absorption, or nutrients containing calcium (see section 4.5), there is a risk of hypercalcaemia and milk-alkali syndrome (See section 4.9). In these patients, serum calcium levels and renal function should be monitored.

Caution is required in patients receiving treatment for cardiovascular disease (see Section 4.5 – thiazide diuretics and cardiac glycosides including digitalis).

Adcal-D3 should also be used with caution in other patients with increased risk of hypercalcaemia e.g. patients with sarcoidosis or those suffering from malignancies.

Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.

Each tablet contains a small amount of sugar (about 1.7 mg per tablet) and may be harmful to teeth if used for a prolonged period.

Allowances should be made for calcium and vitamin D supplements from other sources.

4.5. Interaction with other medicinal products and other forms of interaction

The risk of hypercalcaemia should be considered in patients taking thiazide diuretics since these drugs can reduce urinary calcium excretion. Hypercalcaemia must be avoided in digitalised patients.

Certain foods (e.g. those containing oxalic acid, phosphate or phytic acid) may reduce the absorption of calcium.

Concomitant treatment with phenytoin or barbiturates can decrease the effect of vitamin D because of metabolic activation. Concomitant use of glucocorticoids can decrease the effect of vitamin D.

The effects of digitalis and other cardiac glycosides may be accentuated with the oral administration of calcium combined with Vitamin D. Strict medical supervision is needed and, if necessary monitoring of ECG and calcium.

Calcium salts may reduce the absorption of thyroxine, bisphosphonates, sodium fluoride, quinolone or tetracycline antibiotics, zinc, strontium ranelate and iron. It is advisable to allow a minimum period of four hours before taking the calcium.

Concomitant treatment with orlistat may reduce absorption of vitamin D.

4.6. Pregnancy and lactation

During pregnancy and lactation treatment with Adcal-D3 should always be under the direction of a physician. During pregnancy and lactation, requirements for calcium and vitamin D are increased but in deciding on the required supplementation allowances should be made for availability of these agents from other sources. If Adcal-D3 and iron supplements are both required to be administered to the patient, they should be taken at different times (see Section 4.5).

Overdoses of vitamin D have shown teratogenic effects in pregnant animals. However, there have been no studies on the use of this medicinal product in human pregnancy and lactation. In humans, long term hypercalcaemia can lead to physical and mental retardation, aortic stenosis and retinopathy in a new born child. Vitamin D and its metabolites pass into the breast milk.

4.7. Effects on ability to drive and use machines

None known.

4.8. Undesirable effects

Hypersensitivity reactions including pruritus, wheezing, urticaria, oropharyngeal swelling and angioedema have been reported in the post-marketing environment.

The use of calcium supplements has, rarely, given rise to mild gastro-intestinal disturbances, such as constipation, flatulence, nausea, gastric pain, diarrhoea. Following administration of vitamin D supplements occasional skin rash has been reported. Hypercalciuria, and in rare cases hypercalcaemia have been seen with long term treatment at high dosages.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme.

Website: www.mhra.gov.uk/yellowcard

4.9. Overdose

The most serious consequence of acute or chronic overdose is hypercalcaemia due to vitamin D toxicity. Symptoms may include nausea, vomiting, polyuria, anorexia, weakness, apathy, thirst and constipation. Chronic overdoses can lead to vascular and organ calcification as a result of hypercalcaemia. Treatment should consist of stopping all intake of calcium and vitamin D and rehydration.

Milk-alkali syndrome may occur in patients who ingest large amounts of calcium.

💬 Ask about this leaflet

Ask anything about Adcal D3 chewable tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacy Guide